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Risk of Cardiovascular Disease and Events in
Transgender Patients undergoing Hormone Therapy
Adrian T. Rainer
Transgender people are a greatly misunderstood population, both from a medical standpoint and
from a societal perspective. With trans people often being the target of misinformed and
inflammatory public discourse (Arlee et al., 2019), it can be easy to forget that these individuals
are patients that have real and complex medical needs.
Gender dysphoria is the distressing incongruence between one’s gender assigned at birth
and their gender identity (American Psychiatric Association, 2020). This incongruence is typically
what motivates trans people to physically transition. Over 80% percent of trans people pursue
cross-sex hormone therapy as the primary treatment for their gender dysphoria (Nguyen et al.,
2018). However, not all trans people experience gender dysphoria (particularly those who have
positive social supports in place), and dysphoria is not considered a requirement to be transgender
or to pursue gender transition (Dargie et al., 2014). Additionally, many trans people do not pursue
CSHRT in any form and instead alleviate dysphoria using other means, including legally changing
their name and gender, pursuing social transition, and/or undergoing surgical interventions
(American Psychiatric Association, 2020).
The goal of CSHRT is to suppress endogenous sex hormones and achieve therapeutic levels
of those hormones within the range of the gender the person identifies as. Transwomen (women
who were assigned male at birth) usually take a daily set of pills consisting of estrogen
preparations, along with antiandrogens and occasionally progesterone (Streed et al. 2017).
Transmen (men who were assigned women at birth) typically are prescribed a weekly or bi-weekly
intramuscular injection of testosterone (Streed et al. 2017). These are generalizations, as goals of
CSHRT may vary from person to person.
The effects of administering cross-sex hormone replacement therapy (CSHRT) to
transgender individuals are well-documented as being effective for alleviating mental distress and
gender dysphoria (Nguyen et al., 2018). However, from a cardiovascular perspective, the longterm effects of CSHRT are not well understood. Most research regarding administration of sex
hormones and cardiovascular health has been obtained from cisgender people (people whose
gender identity aligns with what was assigned at birth), which is problematic due to marked
differences in dosing, duration of therapy, and comorbidities between transgender and cisgender
populations (Pyra et al., 2020). This lack of information may make it difficult for healthcare
providers to administer safe and effective evidence-based practice to trans people. Healthcare
providers have a responsibility to serve each population without judgement, and to understand
risks associated with the medications that patients are prescribed. If the time is not taken to research
and understand the full risks and benefits of CSHRT, healthcare providers may be unable to fulfill
their duty as patient educators.
When trans people initiate CSHRT, they must sign informed consent paperwork indicating
that they understand that the full medical effects and safety of CSHRT are not fully known (Schulz,
2017). Once initiated, most transgender individuals will continue taking CSHRT for the rest of
their lives (Nguyen et al., 2018). This leaves the over 1,000,000 trans people currently taking
hormone therapy uninformed as to the cardiovascular risks associated with these medications
(Nguyen et al., 2018). Considering the potential for compounding negative effects over a lifetime
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of taking the same medications, it is necessary for research on this topic to stay appropriately up
to date. The purpose of this article is to analyze the cardiovascular risks associated with taking
CSHRT.
Literature Review
Though there are many gaps in medical literature regarding transgender medical needs, the topic
chosen to discuss in this paper is the risk of cardiovascular disease and acute events that come with
undergoing cross-sex hormone therapy. Specifically, this paper seeks to answer the question of
what the rate of cardiovascular disease is among transgender patients receiving CSHRT when
compared to the general population who are not taking CSHRT.
I.

Literature Search Strategy
A comprehensive literature search occurred during the month of September 2021 on the
Cumulative Index of Nursing and Allied Health Literature (CINAHL) database. Due to the body
of research on this topic being rather limited, relevant literature from any year of publication was
accepted. Key terms included in the database search include transgender, male-to-female, femaleto-male, transsexual, cardiovascular disease, heart disease, hypertension, HTN, venous
thromboembolus, VTE, deep vein thromboembolus, DVT, thromboembolus, TE, risk of, chance,
and probability. To be included in this review, literature had to be published in English. Literature
had to include data on transmen and transwomen taking CSHRT; studies on cisgender men taking
testosterone and cisgender women taking any female hormone preparations were excluded. Lastly,
literature had to contain data related to cardiovascular disease, including but not limited to at least
two of the following: hypertension (HTN), incidence of thromboemboli (including ischemic stroke
and/or pulmonary embolus), myocardial infarcts, lipid levels, diabetes, and coronary heart disease.
Under these constraints, five results met the criteria.
This review will categorize each piece of literature according to the Fineout-Overholt et al.
(2010) hierarchy of evidence, which ranks literary evidence on a scale of 1-7. The highest level of
evidence examined in this review is a level one, performed by Streed et al. (2017). Evidence levels
two and three require controlled trials with placebo groups, and although these types of trials would
be ideal to evaluate the effect of CSHRT on cardiovascular outcomes, withholding treatment to
trans people render placebo groups unethical due to the known psychological benefits that CSHRT
has on the transgender population (Streed, 2017). Thus, this review contains no level two or three
evidence. Level four evidence consists of well-designed cohort studies, of which this review
contains four (Pyra et al. 2020, Getahun et al. 2018, Caceres et al. 2019, Wierckx et al. 2013).
II.

Level One Evidence
The study with a level one tier of evidence done by Streed et al. (2017)
systematically reviewed 13 studies on the effects of CSHRT on the rates of cardiovascular disease
(CVD) in transgender men and women. This study’s goal was to highlight the key research on the
relationship between transgender adults taking CSHRT and the incidence of CVD. This study’s
biggest strength is the fact that 13 different studies were included, giving us a better idea CVD risk
in different populations of transgender individuals across the United States. The researchers
systematically searched PubMed and EMBASE and extracted the relevant data from those studies
to use in the systemic review.

https://repository.stcloudstate.edu/joss/vol2/iss1/1

2

Rainer: Cardiovascular Risk in Transgender Hormone Therapy

This study found that transwomen who were taking high-dose oral estradiol were found to
have a 20- to 45-fold increase in the incidence of thromboembolus (TE) when compared to
ciswomen. Transwomen on transdermal hormones had significantly lower risks of TE (with rates
nearly identical to ciswomen) than transwomen on the high-dose oral estradiol. Transwomen had
a higher risk of MIs when compared to ciswomen of similar risk factors, but a similar risk of MI
when compared to cismen. There were no studies that showed significant differences in the amount
of high-density or low-density lipid levels in transwomen taking CSHRT.
In this review, the researchers found that transmen taking CSHRT didn’t have a statistically
significant increase in the risk of acute cardiovascular events (including TIAs, MIs, and TEs) when
compared to cismen or ciswomen. The studies included in this systematic review also revealed
conflicting results regarding the relationship between transmen on CSHRT and the rate of
hypertension (HTN).
Of the 13 studies included in this review, six of them had sample sizes of less than 30
individuals. These small sample sizes, combined with the weak correlation between CSHRT and
cardiovascular events and diseases in transmen, indicate that longitudinal studies with larger
cohorts of various ages are needed to reach a more definitive answer to this question.
III.

Level Four Evidence
The first level four piece of literature reviewed regarding this topic is an observational
study by Pyra et al., published in 2020 in the journal Transgender Health. This study utilized a
retrospective cohort at a Chicago health center of 6,512 transgender participants on CSHRT to
examine the relationships between transgender individuals taking CSHRT and the incidence of
HTN and TE. A strength of this study is the fact that this study has an exceptionally large sample
size. This study adjusted for factors such as age, race, insurance type, HIV status, sexual
orientation, body mass index, diabetes status, and smoking status, and time elapsed since first
prescribed CSHRT. A limitation of the study is that surgical history data was not available, so
endogenous hormone production (which may be a major factor in CVD risk) was not accounted
for. Additionally, any data on cardiovascular drugs or hormones prescribed outside of the clinic
was unable to be accessed by the researchers.
The results of this study showed that among transwomen, 0.8% (19) experienced a
thromboembolism (TE). There were no associations between rate of TE and the blood levels of
either estradiol or testosterone in transwomen. Transwomen who were recently prescribed
progestin or medroxyprogesterone acetate had odds that increased nearly threefold of experiencing
TE, after adjusting for the relevant risk factors. The sample size was too small for conclusions to
be drawn, but TE is still regarded generally as being a rare event among transwomen, even among
those taking progestin or medroxyprogesterone acetate. Hypertension in transwomen was
experienced by 2.1% (49) of the cohort. The study found that a history of taking progestin was
protective against development of HTN in transwomen, but that a history of oral use of estrogen
appeared to increase rates of HTN.
Among transmen, only 0.2% of the cohort (3 participants) developed thromboembolism,
thus no further association analyses were done as no meaningful conclusions would have been able
to be drawn due to small sample size. The transmen in the study experienced HTN at a rate of
1.5% (28). There appeared to be no relationship between the levels of testosterone in the blood
and the rate of HTN, thus no meaningful conclusions were able to be drawn.
The next piece of level four research was published by Emory University (Getahun et al.
2018). This study was done on a California-based cohort of 2842 transwomen and 2118 transmen,
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and evaluated the relationship between CSHRT and TE, ischemic stroke, and myocardial
infarction. These researchers utilized an electronic health record to identify transgender patients
currently taking CSHRT, and then matched each individual transgender participant to 10 cisgender
male and 10 cisgender female counterparts based on age, race, and geographic location. These
cisgender counterparts were used as a comparison group for the transgender participants. The
pairing of the transgender cohort with a total of 20 cisgender people per one transgender person is
this study’s biggest strength, as the cohort of transgender people is already exceptionally large at
nearly 5,000 participants. As with the study by Pyra et al. (2020), this study was unable to control
for hormones and medications prescribed outside of the clinic which the data was pulled from.
For transwomen taking estrogen, this study found an increased likelihood of TEs. When
calculated as the number of cases per 1000 person-years, transwomen on estrogen had a 6.6 chance
of acquiring a TE, compared to cisgender women at 3.2 and cisgender men at 2.5. This is over a
twofold increase of TE risk when compared to cisgender individuals. For ischemic stroke,
transwomen had an incidence rate of 6.6, whereas cisgender women had a rate of 3.2 and cisgender
men had a rate of 2.9. Myocardial infarct rates were the only ones in which transgender women
were at a lower risk than cisgender women. Transwomen had an incidence rate of 1.5, and
cisgender women had an incidence rate of 2.4. Cisgender men had lower rates of myocardial infarct
than cisgender or transgender women, at 1.0 case per 1000 person-years.
For transmen, this study found that those taking testosterone are at an increased risk of TE
when compared both to cisgender men and cisgender women. Calculated as number of cases per
1000 person-years, transmen experienced VTE at rates of 3.1, whereas cisgender men and women
experience VTE at rates of 1.6 and 1.1, respectively. Rates of myocardial infarct were higher
among transmen taking testosterone (1.2) than in cisgender women (0.7) but were similar to rates
observed among cisgender men (1.3). Lastly, this study shows that transmen had a nearly twofold
risk for ischemic stroke (2.1) when compared both to cisgender men (1.1) and cisgender women
(1.3).
The next piece of level four medical literature was published by Columbia University’s
School of Nursing (Caceres et al., 2019). The researchers used data from the Behavioral Risk
Factor Surveillance System (BRFSS) to examine the relationship between cardiovascular disease
and condition risk to gender identity in United States adults. This study is notable because the
researchers surveyed the participants’ health behaviors, as these are a major factor in the likelihood
of developing cardiovascular disease or experiencing acute cardiac events. This study utilized both
standard odds ratios and adjusted odds ratios. The adjusted odds ratios were based upon risk factors
identified while surveying the participants’ health behaviors, body mass index, age, employment
and marital status, and medical coverage. The following description will include only the adjusted
odds ratios.
This study found that transgender women were 38% more likely than cisgender men and
124% more likely than cisgender women to have any kind of cardiovascular disease (the
researchers did not differentiate between any cardiovascular diseases). Transgender men were 3%
less likely than cisgender men, but 60% more likely than cisgender women to develop
cardiovascular disease. The odds of transgender men or women developing ischemic stroke were
much different. Transgender women were 62% more likely than cisgender men and 88% more
likely than cisgender women to have experienced an ischemic stroke. Transgender men, however,
were 55% more likely than cisgender men and 80% more likely than cisgender women to have
experienced an ischemic stroke. Overall, this study found that transgender women were the group
at the highest risk to develop diabetes, coronary heart disease, stroke, myocardial infarct, and any
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kind of cardiovascular disease when compared to cisgender men, cisgender women, and
transgender men.
A limitation of this study is that it did not examine blood concentration levels of CSHRT,
nor did it examine prescription dosage of CSHRT. This makes it difficult to draw definite
conclusions upon the relationship between CSHRT and cardiovascular events and disease. If we
assume that the transgender people in this study were taking CSHRT at similar dosages as the
transgender people in other studies, then this study strongly suggests that taking exogenous
estrogen is a risk factor for developing cardiovascular disease or experiencing cardiac events in
transgender women. Lastly, this data is only cross-sectional and self-reported, meaning that
lifetime behaviors are not being taken into account and that this study may be prone to bias on
behalf of the participants.
The final level four study reviewed in this paper is one done by Wierckx et al. in 2013.
This study utilized an electronic health record to identify people diagnosed with gender dysphoria
who underwent at least three months of CSHRT, and then sent out an invitation to participate in
the study by letter to the possible participants. This study received a 54% response rate, with a
total of 352 transgender participants. Both cohorts of transgender people got age-matched to 10
female and 10 male counterparts to compare data with regarding cardiovascular disease. The data
is presented in cases per 1000 persons.
This study revealed that transwomen had a relatively high incidence of TE (60.7),
especially when compared with transmen (14.5). This study also revealed that transwomen had
higher incidences of cardiovascular disease (23.4) when compared both to the group of control
men (9.4) and control women (14.9). Additionally, the transmen in the study had zero cases of
cardiovascular disease. Compared to the control men and women who both had the same number
of cases per 1000 people (7.3), this is much lower. These findings suggest that oral estrogen
preparations significantly raise an individual’s risk of acquiring cardiovascular disease when
compared to control groups, and that testosterone preparations do not significantly affect
cardiovascular health outcomes.
A major strength of Wierckx et al.’s (2013) study is that they controlled for BMI, which
many others did not. Furthermore, the median number of years that the participants had been taking
CSHRT was approximately 10, giving us a better idea of the level of CVD risk after many years
of CSHRT. However, only 54% of those invited to participate in the study participated, making
selection bias on behalf of the volunteers a possibility. Lastly, the sample size of 352 people total
was too small to determine an accurate prevalence of morbidity and mortality.
Synthesis
This literature review evaluated five different scientific studies examining the effect that CSHRT
has upon the cardiovascular health of the transgender population. This examination revealed three
main themes: Risk of TEs in transwomen, risk of TEs in transmen, and route of CSHRT
administration in transwomen.
I.

Rate of TEs in transwomen
Every article reviewed examined the general cardiovascular risk posed to transgender
women taking CSHRT, but not every article recorded the instances of the same kinds of CVD; For
example, although every piece of literature examined rates of TEs, only one studied rates of MI.
Thus, this part of the synthesis will focus only the instance of TEs in transwomen, as that is

Published by The Repository at St. Cloud State, 2022

5

SCSU Journal of Student Scholarship, Vol. 2, Iss. 1 [2022], Art. 1

recorded in every study. The articles used many different methods of calculating risk of TE,
including number of cases out of 1000 person-years (Getahun et al. 2018, Streed et al. 2017),
adjusted odds ratios (Wierckx et al. 2013), and percentage points (Pyra et al. 2020, Caceres et al.
2019).
Pyra et al. (2020) found that 0.8% of the transwomen in their study had experienced a TE
in the past. In the study done by Getahun et al. (2018), they found that 6.7 percent of transwomen
experienced a TE at any point during their eight-year study (over twice as likely as any other
group). Caceres et al. (2019) determined that transwomen were 62% more likely to experience a
TE than cisgender men, and Wierckx et al. (2013) determined that transgender women had a 5.1%
chance of experiencing a TE in their lifetime. The systematic review done by Streed et al. (2017)
showed that the most conservative estimates determined transwomen to have a 5.1% rate of TEs
in a lifetime. Despite having different methodologies and methods of calculating risk, every article
agrees that transwomen are at the highest rates of TEs when compared to cisgender men, cisgender
women, and transgender men.
II.

Rate of TEs in Transmen
Because transmen have unique biological profiles when compared to cisgender men,
cisgender women, and transgender women, they too were found to have experienced different rates
of TE when compared to any of the above groups. Like above, the measures used to record rates
of TE among transmen varied from study to study, however general takeaways can still be gleaned
from the information presented in the studies regarding transmen and TEs.
In Pyra et al.’s study (2020), they found that only 0.2% (three participants) of the cohort
developed a TE; because so few developed TEs, no meaningful conclusions could be drawn.
However, it does show TEs not being a common occurrence among transmen. Getahun et al.
(2018) found evidence to support that transgender men experienced TEs at about twice the rate of
cisgender men and three times the rate of cisgender women. Caceres et al. (2019) showed that no
differences in rates of TEs were observed between transmen and cisgender women, but that
transgender men had a 45% higher rate of TEs than cisgender men.
In contrast, Wierckx et al. (2013) showed that transmen had a 1.4% chance of having a TE
in their lifetime (compared to 6.07% of transwomen); However, this study did not examine rates
of TE among their cisgender participants, so it is unknown exactly how this would have compared
to cisgender men or women. Lastly, Streed et al. (2017) was not able to find convincing evidence
in the systematic review that there was any statistically significant increase at all when looking at
TEs in transmen. The evidence for transmen is less conclusive than that of transwomen, but this
may be due to the generally smaller sample sizes for transmen when compared to the sample sizes
for transwomen included in the studies.
III.

Route of CSHRT Administration in Transwomen
The last common theme identified is the difference that CSHRT routes have on TE risk.
Not all CSHRT is administered via the same route, and four of the five studies examined here
distinguish between the routes of CSHRT administration and risk of developing TE. In the United
States, the most common routes of administration of CSHRT for transwomen include
intramuscular injections, transdermal patches, and oral preparations (Nguyen et al. 2018). For the
purpose of this synthesis, “high-dose oral estrogen preparations” have been defined as any oral
estrogen prescription equal or greater than 100mg daily. Transgender men overwhelmingly take
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CSHRT via intramuscular injections (Streed et al. 2017), so there are no meaningful comparisons
that can be made regarding route of CSHRT in transmen and the risk of TE.
Transwomen in Pyra et al.’s (2020) study who were taking oral progesterone
(medroxyprogesterone acetate) experienced TEs at nearly three times the rate of transwomen not
taking progesterone orally, or those who were not taking progesterone at all. Getahun et al. (2018)
found that transwomen who were taking high-dose oral estrogen were twice as likely to get a TE
when compared to cisgender women taking low-dose oral estrogen preparations. Wierckx et al.
(2013) found that their rate of TE in 5.1% of the participants was lower than that of a similar study
done in 1997 (Van Kesteren et al.), which showed transwomen having a 6.4% chance of acquiring
a TE; Interestingly, proportionally fewer people in Wierckx et al.’s (2013) study were on highdose oral estrogen when compared to Van Kesteren et al.’s (1997) study, leading these researchers
to suggest that high-dose oral estrogen preparations are the reason for this difference. In the
systematic review performed by Streed et al. (2017), one study was noted in which a cohort of 816
transwomen receiving CSHRT contained 36 participants who developed TEs; Of these 36
participants, 35 were taking high-dose oral estrogen preparations. However, it is very important to
note that prescriptions of high-dose oral estrogen preparations for transwomen are not the norm,
nor are they recommended practice due to this known risk of the development of TEs (Streed et
al. 2017).
IV.

Unanswered Questions
Because transgender people were systematically denied CSHRT administration from
healthcare professionals until as recently as the 1980s, there is still much research to be done
concerning the effects it has on the cardiovascular system (Naz Khan, 2016). For example, there
are currently no studies able to be found on the risk of cardiovascular disease in older trans people
taking CSHRT. Because cardiovascular risk increases with age in the cisgender population, it is
important for elderly transgender people on CSHRT to know how and if these risks change with
age. Additionally, it is unknown how long-term administration of CSHRT affects cardiovascular
health. Because people are getting access to CSHRT at earlier ages, soon there may be people who
are only in their mid-thirties who have been receiving CSHRT for over 20 years. It is unknown if,
for these individuals, cardiovascular risks “level out” to rates closer to their cisgender counterparts,
or if transgender individuals on CSHRT will always be at an increased risk.
V.

Future Recommendations
Future studies on the topic of transgender cardiovascular health should focus on the risks
associated with taking CSHRT over time, and on whether the potentially harmful cardiovascular
effects of CSHRT compound over time. This can be achieved by designing a long-term
observational study that observes the type and dose of CSHRT, the age at which CSHRT was
initiated, and the current age of the participants, along with relevant cardiovascular risk factors.
Were this review able to include many participants of diverse age, it may be able to answer the
first two unanswered questions listed above. Lastly, more studies are necessary to analyze whether
transgender people are aware of the risk to physical health that CSHRT can pose, and if they are
aware that different medication regimens have different levels of cardiovascular risk associated
with them.
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Conclusion
This literature concludes that CSHRT may have some negative effects on the cardiovascular health
of transwomen, and that current evidence is insufficient to declare what effect CSHRT may have
on transmen. Healthcare providers should be aware that different dosages and formulations of
CSHRT (namely high-dose oral estrogen) may put patients at higher risk of adverse cardiac
outcomes. Although CSHRT may have some adverse effects on the cardiovascular system, the
psychological benefits these individuals experience when utilizing CSHRT often outweigh the
cardiovascular dangers. Patients should be educated on the cardiovascular risk factors associated
with CSHRT prior to initiation. Lastly, it is important that in patients undergoing CSHRT, medical
professionals prioritize monitoring for and educating on modifiable cardiovascular risk factors,
such as smoking, physical inactivity, and high BMI to best maintain the health of these patients.
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